Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$104.68 USD
+0.49 (0.47%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $104.64 -0.04 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$104.68 USD
+0.49 (0.47%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $104.64 -0.04 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
by Zacks Equity Research
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
Stereotaxis (STXS) Achieves CE Mark in Europe for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gets a CE mark in Europe for its GenesisX robotic system. Following this, the company also submits a 501(k) application for FDA clearance.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
by Zacks Equity Research
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.52% and 0.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -89.36% and 55.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Zimmer (ZBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Generative AI-Based MedTech Stocks to Keep an Eye On
by Moumi Mondal
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi
by Zacks Equity Research
Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.
Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance
by Zacks Equity Research
Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.
Zimmer Biomet (ZBH) Procedure Recovery Aids Amid Macro Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to record strong procedure volume in 2024 in both the Knees and Hips businesses, banking on an improved market scenario.
Zimmer Biomet (ZBH) Unlocks Growth Plan for Future Success
by Zacks Equity Research
Zimmer Biomet (ZBH) outlines a path for compelling and long-term topline growth, improved operational profitability, and increased free cash flow generation.
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet
by Zacks Equity Research
Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet are included in this Analyst Blog.
Top Stock Reports for Amazon.com, Visa & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Visa Inc. (V) and Pfizer Inc. (PFE).